NCT01458730View on ClinicalTrials.gov

Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

October 31, 2010

Study Completion Date

August 31, 2022

Conditions
Central Nervous System Lymphoma
Interventions
DRUG

Immunochemotherapy

Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Iphosphamide, Vincristin, Vindesin, Temozolomide, Depocyte

Trial Locations (1)

DK-8000

Elisa Jacobsen Pulczynski, Aarhus

Sponsors
All Listed Sponsors
collaborator

Nordic Cancer Union

OTHER

collaborator

Roche Pharma AG

INDUSTRY

collaborator

Mundipharma Pte Ltd.

INDUSTRY

collaborator

Schering-Plough

INDUSTRY

lead

University of Aarhus

OTHER